John Zajicek

Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon

Alan J. Thompson, Jeremy Hobart, Sj Cano, 2007 .

USING NHS PRIMARY CARE DATA TO IDENTIFY UNDIAGNOSED DEMENTIA

Camille Carroll, Athanasios Anastasiou, Emmanuel Jammeh, 2015, Journal of Neurology, Neurosurgery & Psychiatry.

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

Jeremy Hobart, John Zajicek, J. Hobart, 2013, The Lancet Neurology.

AN ATLAS OF MULTIPLE SCLEROSIS.

John Zajicek, J. Zajicek, 2000 .

Data modeling methods in clinical trials: experiences from the clinical trial methods in neurodegenerative diseases project

Athanasios Anastasiou, Emmanuel Ifeachor, John Zajicek, 2011, Trials.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

James Shearer, David J. Miller, Jeremy Hobart, 2015, Health technology assessment.

2011 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC)

Emmanuel Ifeachor, John Zajicek, E. Ifeachor, 2011, EMBC 2011.